Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here’s Why That’s About to Change.
Vertex is expanding beyond its cystic fibrosis franchise.
Mindfully Curated
Vertex is expanding beyond its cystic fibrosis franchise.
The growth rate for the company’s AI business last quarter was mind-boggling.
AI agent payments are taking off, and that’s good news for Solana.
Two of the largest midstream businesses, but one has more to gain from AI’s intense demand for electricity.
Netflix shares have tumbled as growth has slowed.
The cloud giant is spending faster than its fastest-growing business is earning.
AMD has had a great run in 2026, but it’s time to move on.
Small but steady investments in the chipmaker could build a meaningful position by 2035.
Iridium’s good earnings news is even better news for Rocket Lab stock.
Donald Trump indirectly broke his Social Security promise — and there are steep consequences.
Crypto has rebounded in recent months, prompting investors to seek opportunities in the sector.
Musk predicted the company could close out 2027 with annual recurring revenue of between $500 billion and $1 trillion.
October is usually a decent month for Bitcoin, but it hasn’t been this time around.
The business payments giant is making yet another stablecoin play.
PepsiCo’s dividend yield has spiked just as the stock price could be poised to recover.
Big changes are happening that could impact retirees and workers alike.
One fund targets developed markets with ultra-low fees and higher yields, while the other emphasizes emerging-market growth with heavy tech exposure.
One stock has trailed a 52% chip rally, and the other is still 63% under its record.
Nvidia has the potential to resume its bull run, given its cheap valuation and strong growth prospects.
SpaceX made IPO history in June. But how will its stock perform one year later?